Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cervical cytology readers reduce false negatives

This article was originally published in Clinica

Executive Summary

The false negative rate for Pap tests should be reduced with the cervical cytology readers reviewed by the US FDA advisory panel this month. Unanimously recommending approval for Neuromedical Systems' Papnet and Neopath's AutoPap analysers on August 7th and 8th (see Clinica No 667, p 1), the Haematology and Pathology Devices Advisory Panel noted that cervical cancer responds favourably to treatment if detected early by Pap test. However false negative rates for Pap tests are on average 25%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT092837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel